We're conquering RSV for the young and old – but more innovation is needed
RSV vaccines have been developed for the young and old but as they are approved how it is ensured they reach patients equally?
bio.newsHere’s the latest on RSV vaccines based on reputable public reporting up to 2024–2025, with a quick update on 2026 developments as available.
Direct answer
- Several RSV vaccines have been approved for older adults (60+) in the U.S. and are increasingly recommended in risk-based vaccination guidelines. The first approvals were Arexvy (GSK) and Abrysvo (Pfizer) in 2023–2024, followed by expanding indications in 2024–2025 to cover broader adult age ranges in some jurisdictions. These vaccines aim to reduce RSV-related lower respiratory tract disease and severe outcomes in high-risk adults and pregnant people for infant protection.[1][2][3]
Key context and what’s new
- Arexvy (GSK) and Abrysvo (Pfizer) were the first RSV vaccines approved in the U.S., with pivotal data showing substantial reductions in RSV-associated lower respiratory tract disease and severe disease in adults 60 and older. These approvals marked a milestone after decades of RSV vaccine research.[3][1]
- Pfizer’s Abrysvo later gained broader indications for adults under 60 at elevated risk, and it remains approved for maternal use to protect infants through vaccination during pregnancy. This expanded the potential protective reach beyond older adults.[2]
- In parallel, ongoing monitoring and guidance from public health bodies (e.g., CDC ACIP) have focused on recommendations for use, target groups, and scheduling ahead of RSV seasons. While initial uptake emphasized older adults, guidance has evolved toward broader risk-based strategies.[4][3]
Notes on regional relevance for Fortaleza, Ceará, BR
- RSV vaccines are introduced and recommended differently by country; Brazil has participated in evaluations of RSV prevention strategies, including maternal vaccination programs in some contexts. Local adoption may depend on national guidelines, regulatory approvals, and supply agreements. If you’d like, I can look for Brazil-specific regulatory status and guidance as it relates to your region.[4]
Illustration (example)
- Think of RSV vaccination in adults as a shield for those at higher risk: a first shield for seniors, with later additions broadening protection for younger at-risk adults and newborns via maternal vaccination. This multi-angle approach mirrors how flu vaccines are used to protect diverse groups.
Would you like me to pull Brazil-specific regulatory updates or current local availability in Fortaleza, including which vaccines are currently recommended by Brazilian health authorities? If you want, I can also provide a brief side-by-side of Arexvy vs Abrysvo (age indications, dosing, and primary trial outcomes).[1][2][4]